Immucura Dublin

9.90

Dublin, Ireland

122

User Score	Rating	Price Range	Media Files	Founded In	Patients	Departments	Age Group	Clinic Type	Type of Care	Size	Online Consultations
98%	9.9/10	$$$$	122	2014	254	4 medical units	Adults	Specialized	Outpatient	Medium	Yes

Overview

Size

Medium

Clinic type

Specialized

Type of care

Outpatient

Age group

Adults

Features & Facts

Therapy for different cancers

From 2020 to 2023, Immucura treatment was applied for various types of cancer, including colorectal cancer, which accounted for 11% of cases. Other common cancers included brain and central nervous system (13%), breast (22%), pancreas (10%), and prostate (8%).

Facts in numbers

Over 1,000 patients have evaluated the benefits of treatment at Immucura and received excellent results. As more patients trust innovative therapy, the annual number of services provided increases permanently.

Numerous advantages

Treatment at Immucura has significant advantages over long-standing methods such as radiation, chemotherapy, or surgery. First, the absence of pain, lack of side effects, and naturalness of the therapy attract patients worldwide.

Prostate cancer in numbers

Stage 4 makes up almost 78% of all prostate cancers treated with Immucura. Regardless of advanced stages, patient survival rates are 100% within the first year of treatment, 83% after 3 years, 80% after 5 years, and 50% after 10 years.

A comprehensive solution

Doctors have developed an сancer defense pack program to restore metabolic processes. Special trace elements can reduce the manifestations of mitochondrial deregulation in cancer cells, significantly improving dendritic cell therapy's efficacy.

Breast cancer under control

Given breast cancer survival rates, Immucura's data is promising. During the 1 year of cure, all patients survived, demonstrating a 100% survival rate. After 3 years, the indicator is 88%, and after 5 years — 79%. Almost 77% of patients have stage 4 cancer, and 79% have metastases.

The latest treatment

Although dendritic cells were discovered in the 19th century, their ability to destroy cancer cells was only invented and proven in 2011. Despite the novelty of the treatment, more than 700,000 clinical articles have already been published.

Promising results for brain cancer

Even though a large number of treatments with dendritic cells are stage 4, the survival rate for brain cancer in the company is relatively high. In particular, during 1 year of treatment, the rate is 69%, 45% after 3 years, and 27% after 5 years.

Powerful protection

Immucura has learned to perfectly apply the possibilities of dendritic cell therapy, which can produce approximately 40 to 60 billion protective cells per day. Killer cells can identify a malignant cell before it multiplies and cause irreparable damage to health.

Stage 4 has a chance

Analysis of the company's statistics over the last years showed that the survival rate of patients with stage 4 colorectal cancer after treatment was 100% within the first year, 60% within three years, and 25% after 5 years. This indicator is much higher than that of standard cure methods.

The sooner, the better

Immucura works with highly complex cases of esophageal cancer and has had statistics for several years. The survival rate for stage 4 during the first year was 40%, and after 2 years, it was 20%. The earlier treatment is started, the greater the chances of success.

Without fear of difficulties

Although more than 90% of pancreatic cancer treated with Immucura is stage 4 in an advanced form, the innovative treatment gives patients a survival rate of almost 42% during the first year. Further research on dendritic cell therapy could be revolutionary.

About the clinic

Immucura is a world-renowned healthcare service provider and leader in dendritic cell therapy (DCT). Since 2014, it has used an innovative approach to treating oncological lesions. By working on cancer's causes and mechanisms, not just the effects, Immucura has decisive advantages over conventional treatments. The approach of Immucura specialists is a holistic strategy to oncology remedy, consisting of the most natural fight against oncology in the form of DCT and additional counseling in nutrition, lifestyle, sleep, breathing sessions, and psychological support. The company's concept is that a healthy person can produce up to 150,000 cancer cells, which are under the control of the immune system and are effectively destroyed. Therefore, oncological disorders develop precisely because of the dysregulation of immune processes and decreased protective effect. Dendritic cell therapy (DCT) can be considered a natural immunotherapy that allows you to treat oncological lesions without introducing pharmaceuticals, chemicals, or external interventions. This approach is much safer and more effective than radiation or chemotherapy. In addition, using the patient's cells and the body's capabilities makes the cure completely personalized, unique, and individual. The DCT procedure is straightforward and involves drawing a 60-180 ml venous blood sample. Dendritic cells will be cultured from the blood monocytes in a unique laboratory for several weeks. Dendritic cells help the immune system recognize and attack abnormal cells. After introducing mature dendritic cells into the body, the immune system strongly reacts to malignant cells and learns to fight against them within 6-9 months. Immune memory transmitter therapy (IMT) can be combined with dendritic cell therapy to enhance immunological memory and effectiveness. In addition, Immucura specializes in nanothermia, or modulated electro-hyperthermia (mEHT), an additional painless anti-cancer remedy with high efficiency due to the use of radio frequencies that penetrate deep tissue layers and the more excellent conductivity of malignant tissues. Activation of the p53 tumor suppressor protein helps suppress the activity of malignant tissues and facilitates their natural death (apoptosis). Numerous positive reviews of the work of the Immucura team combined with the high treatment efficiency results are not without reason. A comprehensive approach to each patient, a thorough analysis of the body's condition, and the impact on the various causes of cancer using the latest medical discoveries in Cancer Health are the drivers of success. The availability of treatment in different countries indicates special care and understanding of the patient's needs.

Departments & Doctors

Dendritic cell therapy

Dr. Riadh Ben Sghaier, MD

immune-driven disease, dentritic cell therapy, and vaccination

Electro-hyperthermia

Nutrition

Psychology

Gallery

Extra services

Language Assistance

Visa Support

Telemedicine

Travel Assistance

Parking Space

FAQ

How long does treatment at Immucura take?

Each treatment plan is discussed individually, and the duration may depend on the presence of concomitant chemotherapy. Generally, growing cells in the laboratory can take 9-21 days from blood sampling.

Should I stop my primary cancer treatment using dendritic cell therapy?

Unlike chemotherapy, cellular immunotherapy is a primary therapy, not just an adjunctive therapy. Also, dendritic cell therapy is well combined with traditional methods of treatment. Exclusion or abandonment is accepted after individual consultation.

If I am unable to travel, can I be treated at home?

Immucura's services cover Europe, offering home flying nurses, online consultations, and collaboration with clinics in the UK, Germany, Austria, Croatia, and the Netherlands. With a well-structured logistics network, Immucura can reach and help patients in many countries.